Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but has led to doctors complaining about their effectiveness.
中國監管機構正在調查國產仿製藥的質量，起因是一項在國家醫療保健體系中優先使用此類藥物的節省成本運動罕見地遭到了公衆的強烈反對，一些醫生抱怨國產仿製藥的療效。
您已閱讀5%（336字），剩餘95%（5783字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。